3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma, Large B-Cell, Diffuse
33
Leukemia, Lymphocytic, Chronic, B-Cell
30
Lymphoma, Mantle-Cell
26
Lymphoma, Follicular
17
Waldenstrom Macroglobulinemia
14
Lymphoma, B-Cell, Marginal Zone
14
Recurrence
12
Lymphoma
12
Lymphoma, B-Cell
9
Lymphoma, Non-Hodgkin
6
Leukemia
4
B-cell Malignancies
3
Neoplasms
2
Hematologic Neoplasms
2
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Mature B-Cell Malignancies
1
Lymphoma, T-Cell
1
Lymphohistiocytosis, Hemophagocytic
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Acute
1
Leukemia, B-Cell
1
Intraocular Lymphoma
1
Hematologic Diseases
1
Dendritic Cell Sarcoma, Interdigitating
1
Congenital Abnormalities
1
Interventions
Cyclophosphamide
20
Brentuximab Vedotin
20
fludarabine
16
Lenalidomide
13
Rituximab
12
Dexamethasone
12
fludarabine phosphate
10
Melphalan
10
Busulfan
10
Mycophenolic Acid
9
dacetuzumab
7
Whole-Body Irradiation
7
Tacrolimus
7
pirtobrutinib
6
Doxorubicin
6
Bortezomib
6
Azacitidine
6
ruxolitinib
5
Vincristine
5
Prednisone
5
Imatinib Mesylate
5
ponatinib
4
pomalidomide
4
Mesna
4
Granulocyte Colony-Stimulating Factor
4
Etoposide
4
Bone Marrow Transplantation
4
Bendamustine Hydrochloride
4
venetoclax
3
nilotinib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Hematologic Diseases
×
zanubrutinib
×
Clear all
NCT04662255
2026-05-15
BRUIN-MCL-321
Eli Lilly and Company
Phase 3
Active not recruiting
500 enrolled